Guizhou Xinbang Pharmaceutical Co Ltd
Guizhou Xinbang Pharmaceutical Co., Ltd. manufactures and sells traditional Chinese medicine and other pharmaceutical products in China and internationally. The company cardiovascular and cerebrovascular, digestive system, endocrine, tumors and immunomodulatory drugs, blood system drugs, rheumatism and rheumatoid arthritis, urinary system, antipyretic and analgesic, cold medicine, gynecological m… Read more
Guizhou Xinbang Pharmaceutical Co Ltd (002390) - Net Assets
Latest net assets as of September 2025: CN¥6.97 Billion CNY
Based on the latest financial reports, Guizhou Xinbang Pharmaceutical Co Ltd (002390) has net assets worth CN¥6.97 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.59 Billion) and total liabilities (CN¥1.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.97 Billion |
| % of Total Assets | 81.17% |
| Annual Growth Rate | 24.09% |
| 5-Year Change | 35.82% |
| 10-Year Change | 163.02% |
| Growth Volatility | 73.3 |
Guizhou Xinbang Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Guizhou Xinbang Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guizhou Xinbang Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual net assets of Guizhou Xinbang Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.02 Billion | -1.71% |
| 2023-12-31 | CN¥7.14 Billion | +1.09% |
| 2022-12-31 | CN¥7.07 Billion | +3.46% |
| 2021-12-31 | CN¥6.83 Billion | +32.12% |
| 2020-12-31 | CN¥5.17 Billion | +2.38% |
| 2019-12-31 | CN¥5.05 Billion | -2.33% |
| 2018-12-31 | CN¥5.17 Billion | -23.53% |
| 2017-12-31 | CN¥6.76 Billion | +4.22% |
| 2016-12-31 | CN¥6.49 Billion | +142.97% |
| 2015-12-31 | CN¥2.67 Billion | +8.59% |
| 2014-12-31 | CN¥2.46 Billion | +137.27% |
| 2013-12-31 | CN¥1.04 Billion | +1.30% |
| 2012-12-31 | CN¥1.02 Billion | +4.40% |
| 2011-12-31 | CN¥979.53 Million | +2.07% |
| 2010-12-31 | CN¥959.70 Million | +279.58% |
| 2009-12-31 | CN¥252.83 Million | +21.73% |
| 2008-12-31 | CN¥207.69 Million | +19.31% |
| 2007-12-31 | CN¥174.08 Million | +20.75% |
| 2006-12-31 | CN¥144.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guizhou Xinbang Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1182.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥456.75 Million | 6.81% |
| Common Stock | CN¥1.94 Billion | 28.97% |
| Other Components | CN¥4.31 Billion | 64.22% |
| Total Equity | CN¥6.71 Billion | 100.00% |
Guizhou Xinbang Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Guizhou Xinbang Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guizhou Qianyuan Power Co Ltd
SHE:002039
|
$639.23 Million |
|
ZWSOFT Guangzhou Co Ltd
SHG:688083
|
$639.37 Million |
|
Daily Journal Corp
NASDAQ:DJCO
|
$639.83 Million |
|
Jiangsu Chengxing Phosph-Chemical Co Ltd
SHG:600078
|
$639.83 Million |
|
Pantoro Gold Ltd
AU:PNR
|
$639.07 Million |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
$639.03 Million |
|
ROMANDE ENERGIE SA
SW:REHN
|
$638.95 Million |
|
Nanjing Develop Advanced Manufacturing Co Ltd
SHG:688377
|
$638.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guizhou Xinbang Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,852,401,000 to 6,710,056,000, a change of -142,345,000 (-2.1%).
- Net income of 101,381,627 contributed positively to equity growth.
- Dividend payments of 192,290,000 reduced retained earnings.
- Share repurchases of 78,985,852 reduced equity.
- Other comprehensive income decreased equity by 201,046,000.
- Other factors increased equity by 228,595,225.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥101.38 Million | +1.51% |
| Dividends Paid | CN¥192.29 Million | -2.87% |
| Share Repurchases | CN¥78.99 Million | -1.18% |
| Other Comprehensive Income | CN¥-201.05 Million | -3.0% |
| Other Changes | CN¥228.60 Million | +3.41% |
| Total Change | CN¥- | -2.08% |
Book Value vs Market Value Analysis
This analysis compares Guizhou Xinbang Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.91x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 14.62x to 0.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.22 | CN¥3.23 | x |
| 2007-12-31 | CN¥0.27 | CN¥3.23 | x |
| 2008-12-31 | CN¥0.32 | CN¥3.23 | x |
| 2009-12-31 | CN¥0.39 | CN¥3.23 | x |
| 2010-12-31 | CN¥1.22 | CN¥3.23 | x |
| 2011-12-31 | CN¥1.15 | CN¥3.23 | x |
| 2012-12-31 | CN¥1.19 | CN¥3.23 | x |
| 2013-12-31 | CN¥1.23 | CN¥3.23 | x |
| 2014-12-31 | CN¥2.15 | CN¥3.23 | x |
| 2015-12-31 | CN¥2.04 | CN¥3.23 | x |
| 2016-12-31 | CN¥3.87 | CN¥3.23 | x |
| 2017-12-31 | CN¥3.94 | CN¥3.23 | x |
| 2018-12-31 | CN¥3.06 | CN¥3.23 | x |
| 2019-12-31 | CN¥3.03 | CN¥3.23 | x |
| 2020-12-31 | CN¥3.11 | CN¥3.23 | x |
| 2021-12-31 | CN¥3.64 | CN¥3.23 | x |
| 2022-12-31 | CN¥3.64 | CN¥3.23 | x |
| 2023-12-31 | CN¥3.58 | CN¥3.23 | x |
| 2024-12-31 | CN¥3.54 | CN¥3.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guizhou Xinbang Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.68%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.35x
- Recent ROE (1.51%) is below the historical average (5.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 12.22% | 10.07% | 0.46x | 2.66x | CN¥3.17 Million |
| 2007 | 17.32% | 13.74% | 0.56x | 2.27x | CN¥12.65 Million |
| 2008 | 16.28% | 12.23% | 0.62x | 2.14x | CN¥12.97 Million |
| 2009 | 18.44% | 13.87% | 0.72x | 1.86x | CN¥21.37 Million |
| 2010 | 3.93% | 11.85% | 0.28x | 1.17x | CN¥-58.26 Million |
| 2011 | 4.70% | 12.73% | 0.29x | 1.27x | CN¥-51.95 Million |
| 2012 | 4.70% | 10.69% | 0.34x | 1.31x | CN¥-53.94 Million |
| 2013 | 3.89% | 7.07% | 0.38x | 1.44x | CN¥-63.25 Million |
| 2014 | 6.04% | 5.85% | 0.47x | 2.18x | CN¥-94.92 Million |
| 2015 | 6.86% | 4.17% | 0.64x | 2.56x | CN¥-79.81 Million |
| 2016 | 3.87% | 4.77% | 0.48x | 1.70x | CN¥-389.19 Million |
| 2017 | 4.83% | 5.32% | 0.50x | 1.81x | CN¥-342.15 Million |
| 2018 | -26.10% | -19.70% | 0.61x | 2.19x | CN¥-1.79 Billion |
| 2019 | 4.89% | 3.55% | 0.64x | 2.15x | CN¥-247.41 Million |
| 2020 | 3.53% | 2.97% | 0.61x | 1.96x | CN¥-318.31 Million |
| 2021 | 4.12% | 4.22% | 0.67x | 1.45x | CN¥-389.11 Million |
| 2022 | 3.30% | 3.53% | 0.65x | 1.44x | CN¥-456.47 Million |
| 2023 | 4.19% | 4.45% | 0.70x | 1.35x | CN¥-398.01 Million |
| 2024 | 1.51% | 1.68% | 0.67x | 1.35x | CN¥-569.62 Million |
Industry Comparison
This section compares Guizhou Xinbang Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,075,411,249
- Average return on equity (ROE) among peers: 9.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guizhou Xinbang Pharmaceutical Co Ltd (002390) | CN¥6.97 Billion | 12.22% | 0.23x | $639.13 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $902.62 Million | 5.17% | 3.60x | $597.12 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.98% | 1.16x | $313.25 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.35 Billion | 7.54% | 0.22x | $3.25 Billion |
| Wedge Industrial Co Ltd (000534) | $643.84 Million | 3.65% | 1.07x | $1.71 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $247.96 Million | 10.36% | 0.27x | $5.35 Billion |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.78 Million | 10.37% | 0.50x | $315.24 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.16 Billion | 6.95% | 1.96x | $416.82 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $720.42 Million | 13.93% | 0.65x | $1.93 Billion |
| Renhe Pharmacy Co Ltd (000650) | $857.16 Million | 19.68% | 0.24x | $748.56 Million |
| Changchun High & New Technology Industries Group Inc (000661) | $451.02 Million | 11.10% | 0.94x | $3.34 Billion |